A network pharmacology approach to reveal the pharmacological targets and biological mechanism of compound kushen injection for treating pancreatic cancer based on WGCNA and in vitro experiment validation

Chao Wu1†, Zhi‑Hong Huang1†, Zi‑Qi Meng1, Xiao‑Tian Fan1, Shan Lu1, Ying‑Ying Tan1, Lei‑Ming You2, Jia‑Qi Huang1, Antony Stalin3, Pei‑Zhi Ye4, Zhi‑Shan Wu1, Jing‑Yuan Zhang1, Xin‑Kui Liu1, Wei Zhou1,5, Xiao‑Meng Zhang1 and Jia‑Rui Wu1*

Abstract

Background: Compound kushen injection (CKI), a Chinese patent drug, is widely used in the treatment of various cancers, especially neoplasms of the digestive system. However, the underlying mechanism of CKI in pancreatic cancer (PC) treatment has not been totally elucidated.

Methods: Here, to overcome the limitation of conventional network pharmacology methods with a weak combination with clinical information, this study proposes a network pharmacology approach of integrated bioinformatics that applies a weighted gene co‑expression network analysis (WGCNA) to conventional network pharmacology, and then integrates molecular docking technology and biological experiments to verify the results of this network pharmacology analysis.

Results: The WGCNA analysis revealed 2 gene modules closely associated with classification, staging and survival status of PC. Further CytoHubba analysis revealed 10 hub genes (NCAPG, BUB1, CDK1, TPX2, DLGAP5, INAVA, MST1R, TMPRSS4, TMEM92 and SFN) associated with the development of PC, and survival analysis found 5 genes (TSPOAP1, ADGRG6, GPR87, FAM111B and MMP28) associated with the prognosis and survival of PC. By integrating these results into the conventional network pharmacology study of CKI treating PC, we found that the mechanism of CKI for PC treatment was related to cell cycle, JAK‑STAT, ErbB, PI3K‑Akt and mTOR signalling pathways. Finally, we found that CDK1, JAK1, EGFR, MAPK1 and MAPK3 served as core genes regulated by CKI in PC treatment, and were further verified by molecular docking, cell proliferation assay, RT‑qPCR and western blot analysis.

Conclusions: Overall, this study suggests that the optimized network pharmacology approach is suitable to explore the molecular mechanism of CKI in the treatment of PC, which provides a reference for further investigating biomarkers for diagnosis and prognosis of PC and even the clinical rational application of CKI.
Introduction
Pancreatic cancer (PC) is a common malignant tumour of the digestive tract characterized by concealed onset, high malignancy, and rapid development, and the majority of PC cases have locally advanced or metastatic at the time of diagnosis [1–3]. According to Global Cancer Statistics, approximately 466,000 deaths (4.7% of total cases) worldwide in 2020 are attributable to PC, which ranks seventh in cancer-related mortality [4]. In countries with a high human development index, such as Europe and North America, the incidence of PC is three to four times higher, and the number of deaths from PC in the United States is expected to increase significantly by 2030, which PC will become the second leading cause of cancer death [4, 5]. PC is one of the worst prognostic tumours among all malignant tumours. Tumour metastasis occurs in about 60% of PC patients when diagnosed. The median survival time of patients is only 6–15 months, and the five-year survival rate is lower than 6%. Human health and life are under severe constant threat of PC [6].

Compound kushen injection (CKI), is made of Kushen (Radix Sophorae flavescentis) and Baituling (Rhizoma Smilacisglabrae) by modern technology [7], has been approved by China Food and Drug Administration (CFDA) in 1995 as an adjuvant drug for cancer treatment, which can relieve pain, activate innate immune response and reduce side effects in cancer treatment [8, 9]. Moreover, CKI has been found to inhibit the tumour cell growth, proliferation, metastasis and invasion, induce tumour cell apoptosis, and have the functions of anti-multidrug resistance and protection of human immune function [10]. The combination of CKI and chem(radio) therapy improves the therapeutic effect and quality of life in PC patients. In addition, CKI has been reported a direct inhibitory effect on human PC cells SW1990 in vitro [11, 12]. However, the anti-PC effect of CKI has been confirmed while the underlying molecular mechanism is still a mystery.

Network pharmacology has become an effective tool to elucidate the complex overall mechanism of traditional Chinese medicine (TCM) and provides a new perspective for analyzing drug effects [13]. In accordance with the TCM characteristics of multi-component, multi-target, multi-pathway synergy, network pharmacology transforms the "one target, one drug" model into a new "multi-target, multi-component" model and clarifies the complex interactions among genes, proteins, and metabolites related to diseases and drugs from a network perspective [14, 15]. But, the limitations such as the clinical information deficiency restrict the value and application of network pharmacology. Zhang and Horvath first developed weighted gene co-expression network analysis (WGCNA) in 2005, which has become a standard algorithm used for gene co-expression network construction [16, 17]. Currently, WGCNA is used in several studies of complex human diseases [18–20], especially in cancers, such as lung cancer [21], breast cancer [22], cholangiocarcinoma [23], etc. Benefiting from it is special function, which can discover modules of highly correlated genes and correlate with modules and external sample characteristics (i.e., associated key genes with clinical features), WGCNA is generalized to various research areas [24]. It conferred more clinical significance to its findings. Coincidentally, this also exactly compensates for the shortage of clinical information loss in network pharmacology.

In the present study, we aim to apply WGCNA to optimize network pharmacology methods. Firstly, WGCNA was used to construct a gene co-expression network, find clusters (modules) of highly related genes, modules and correlate with external sample traits. And then, we screened the relevant modules to obtain biomarkers that were closely related to PC development. Survival analyses were employed to identify hub genes affecting the pathogenesis and prognosis of PC patients. In addition, we constructed a "compound-putative target network", “CKI-PC The protein–protein interaction (PPI) network”, “drug-compound-PPI target-pathway network” through the network pharmacology method to explore the mechanism of CKI in the treatment of PC. This study aimed to reveal the complex mechanism of multi-component, multi-target, and multi-pathway of CKI in the treatment of PC at a system level, and provide a better basis for the diagnosis, treatment and prognosis of PC. Figure 1 shows a flowchart of the network pharmacology approach used in this study.

Materials and methods
Data collection and preprocessing
RNA sequencing data of pancreatic adenocarcinoma, containing a total of 182 samples, were obtained from The Cancer Genome Atlas (TCGA) database [25]. After removing non-cancerous samples and metastatic tumour samples, 177 primary tumour samples were obtained for further analysis. The “goodSamplesGenes” function in

(See figure on next page.)

Fig. 1 The flowchart of network pharmacology approach used in this study for exploring the molecular mechanism of CKI treating PC
Fig. 1 (See legend on previous page.)
Interconnectedness. According to the dissimilarity matrix, which represents the connection relationship of genes, cluster analysis of genes by dissimilarity was performed to construct a hierarchical cluster tree [26]. The dynamic tree-cut algorithm method was adopted to identify the module of gene co-expression with values maxBlockSize = 6000, minModuleSize = 30 and mergeCutHeight = 0.2. Module eigengene (ME) refers to the first principal component of each gene module, and the expression of ME is considered to represent all genes in a module. The most important module can be found by calculating the correlation coefficient between ME and the clinical traits of interest. Gene significance (GS) indicates the degree of correlation between individual genes and clinical information. For each module, module membership (MM) is defined as the correlation between a single gene and ME, used to measure the importance of this gene in the module. According to ME, GS and MM, we can associate modules with clinical traits, not only to calculate the correlation between ME and clinical traits, but also to analyze clinically important modules.

### Identify hub genes and external validation

CytoHubba [27], a plug-in of Cytoscape software [28], is available for exploring important nodes of biological networks. In this study, Cytoscape was employed to visualize the module network, and CytoHubba was used to analyze the network. The maximal clique centrality (MCC) algorithm was then selected to determine the top 5 genes with the highest scores among the important modules as hub genes.

Then, we selected the data in the GEO database as the external validation dataset. We searched the GEO database using the term “pancreatic cancer” and the criteria for inclusion of PC chip datasets were to meet the following: ① Patients newly diagnosed with pancreatic cancer and not receiving any treatment; ② Datasets with total samples greater than 50. We performed differential expression analysis after normalizing and homogenizing raw data using the limma package in R, followed by Benjamini & Hochberg (false discovery rate) correction of p-values.

### Survival analysis

In this study, a univariate Cox proportional hazards regression analysis was performed for the genes in the selected modules using the survival package to identify

---

**Table 1 qPCR primer sequence**

| Gene  | 5' to 3'                 |
|-------|--------------------------|
| AKT1  | Forward: TCTATGCGGCTGAGATTGGT | Reverse: CTTAATGTGGCCGCTCCTGT |
| CDK1  | Forward: TAGGGGGAATCATTACCACC | Reverse: TCAATGGTACACTGAGCTC |
| EGFR  | Forward: TGTGCCCACTATCGTTGAGCG | Reverse: TAGCCCCATCGTTGGACAG |
| JAK1  | Forward: AGGGGATGGCAATTTTGGTTCTC | Reverse: CCTATCGGTTTCAATTGTGTGG |
| MAPK1 | Forward: GGAACATTTTGCTTCTCCTCC | Reverse: CTACTTCAATCTCGTTGTG |
| MAPK3 | Forward: ATCAACCACCGCTGGACCTTA | Reverse: TACACGCGGTAGCCACATCT |

(See figure on next page.)

**Fig. 2** Construction of co-expression module. A Soft-thresholding powers analysis. R² = 0.85. B Cluster diagram of gene modules. Different colors represent different gene modules, and gray modules are composed of genes that do not belong to any module. C Network TOM heatmap plot. TOM plot was made up by randomly selected 400 genes. Each row and column represented a module and the genes of the module. This diagram showed the degree of correlation within the module. D Module–trait relationship. Each row corresponds to a ME, and each column corresponds to a clinical trait. Each cell contains a corresponding correlation and P-value of modules with various clinical traits.
Fig. 2 (See legend on previous page.)
candidate genes strongly correlated with survival. Subsequently, candidate genes that screened according to P-value were entered into the multivariate Cox proportional hazards regression analysis. Based on the selected gene expression profile, a survival-related linear risk assessment model was constructed. The formula for calculating the prognostic risk score is:

$$\text{risk score} = \sum_{i=1}^{n} (\exp_i \times \text{coefficient}_i)$$

Using the median prognostic risk score as a cut-off value, samples were divided into high- and low-risk groups. Furthermore, the correlation between gene expression and survival time was confirmed by calculating the hazard ratio (HR) and 95% confidence interval (CI). The Kaplan–Meier and Log-rank test methods were used to evaluate the differences in overall survival rates between the high- and low-risk groups. The survivalROC package analyzed a time-dependent receiver operating characteristic curve (ROC curve) to evaluate the prediction accuracy of the prognostic signature for time-dependent cancer death. Moreover, the predictive ability of the gene signature for clinical outcomes was measured by calculating the area under the curve (AUC).

Identification of CKI compounds and targets
CKI (batch number: 20200329) was supplied by Zhendong Pharmaceutical Co. Ltd (Shanxi, China). Shimadzu Nexera LC-40-QE-Orbitrap-MS Separation was performed on an analytical column of Hypersil BDS (150 mm × 4.6 mm, 5 μm). The oven was set at 25 °C; The injection volume was 5 μL; The flow rate was set at 0.5 mL min⁻¹; The mobile phase was consisted of 0.1% ammonia in water (A) and carbinol (B). The eluting program was: 5–20% B for 0–1 min, 20–80% B for 1–30 min, 80–60% B for 30–60 min. The ion source was electrospray ionization (ESI); MS was operated in positive/negative mode; The scan mode was Full scan/ddMS2; The scan range was 100–1200 Da; The capillary temperature was 350 °C; The spray voltage in negative mode was 3800 V; The spray voltage in positive mode was 3200 V; The sheath gas was 35 arb; The aux gas was 15 arb; Three collision energies of low, medium and high were used for MS2. The positive ion mode was 30 eV, 40 eV, 50 eV, and the negative ion mode was 30 eV, 50 eV, 70 eV. The resolution of the Full scan was 70,000 FWHM, and the resolution of MS2 was 17,500 FWHM. The reference marker compounds present in the sample were identified based on retention time, MS fragmentation and UV spectra.

Then, the structural information of the CKI compounds was retrieved from the PubChem database [29] (https://pubchem.ncbi.nlm.nih.gov/). The simplified molecular input line entry specification (SMILES) of these compounds were imported into four databases, Search Tool for Interactions of Chemicals (STITCH) [30], SuperPred [31], SwissTargetPrediction [32], and Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP) [33], to collect the known and predicted human targets of these compounds.

Collection of PC targets
The human genes associated with PC were obtained from three resources: (1) 10 hub genes related to the occurrence and development of PC and 5 potential biomarkers closely related to prognosis obtained from WGCNA; (2) Therapeutic Target Database (TTD) database [34]. The TTD database was searched using the key word "pancreatic cancer"; (3) TCGA database. RNA sequencing data of pancreatic adenocarcinoma were obtained from the TCGA database.

Data were normalized and analyzed by the edgeR package [35]. Differential expression genes (DEGs) were then screened out using $|\log_{2}(FC)| > 1$ and adjust $P < 0.05$. The PPI data were extracted from the Search Tool for the Retrieval of Interacting Genes (STRING, https://stringdb.org/) database [36]. The PPI data with the species limited to "Homo sapiens", and the confidence score greater than 0.7 (high confidence) were selected for further investigation.

Network construction
In this study, we constructed three networks: (1) compound-putative target network was built by connecting CKI compounds and their related targets; (2) CKI-PC PPI network was constructed by connecting the intersections of the compound targets and PC-related targets and other human proteins interacting with them; (3) drug-compound-PPI target-pathway network was constructed by connecting CKI, compounds, PPI targets, and related pathways. The above networks were visualized using Cytoscape and the topological features of the interaction networks were evaluated by calculating three indices (degree, betweenness, closeness) using the NetworkAnalyzer plug-in.
Fig. 3 (See legend on previous page.)
Module analysis and enrichment analysis

To identify the core clustering module in the CKI-PC PPI network, the plug-in Molecular Complex Detection (MCODE) in Cytoscape was used for module analysis. DAVID (https://david.ncifcrf.gov/, version 6.8) [37] was employed to perform Gene Ontology (GO) function enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis for the selected modules. The significance threshold was set at $P < 0.05$ and the false discovery rate (FDR) was set at $< 0.05$.

Molecular docking

The three-dimensional crystal structures of the core target were extracted from the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Database [38] (PDB, https://www.RCSB.org/). Then, the protein structures were processed by AutoDock Tools (ADT) [39], including removal of ligands and water molecules, calculation of Gasteiger charge, addition of polar hydrogen, and combination of non-polar hydrogen. ADT was also utilized to prepare corresponding compounds. Subsequently, molecular docking was carried out via AutoDock Vina [40]. Finally, the receptor-ligand complex was imported into Ligplus software to analyze the hydrogen bonding and hydrophobic interaction between the receptor and ligand.

Cell lines and cell proliferation assays

Human PC cell lines Panc-1 was purchased from Procell Life Science &Technology Co., Ltd. (Wuhan, China), and cultured in Dulbecco's modified Eagle's medium (DMEM, Corning, USA) containing 10% fetal bovine

---

**Table 2** Preliminary screening of single-factor Cox proportional hazard model

| Gene      | Coef | Exp (coef) | z     | P value       | Lower. 95 | Upper. 95 |
|-----------|------|------------|-------|---------------|-----------|-----------|
| MET       | 0.600| 1.822      | 5.595 | 2.200E−08     | 1.476     | 2.247     |
| ARNTL2    | 0.569| 1.766      | 5.402 | 6.580E−08     | 1.437     | 2.171     |
| TLE2      | −0.698| 0.498      | −5.176| 2.270E−07     | 0.382     | 0.648     |
| FAM83A    | 0.202| 1.224      | 5.041 | 4.630E−07     | 1.132     | 1.325     |
| KIF23     | 0.564| 1.758      | 4.960 | 7.040E−07     | 1.407     | 2.196     |
| ANLN      | 0.458| 1.580      | 4.919 | 8.680E−07     | 1.317     | 1.896     |
| LAMA3     | 0.412| 1.510      | 4.877 | 1.080E−06     | 1.279     | 1.781     |
| NUSAP1    | 0.671| 1.957      | 4.805 | 1.550E−06     | 1.488     | 2.573     |
| TSPOAP1   | −0.400| 0.670      | −4.784| 1.720E−06     | 0.569     | 0.790     |
| ECT2      | 0.590| 1.805      | 4.775 | 1.800E−06     | 1.416     | 2.300     |
| FAM111B   | 0.617| 1.854      | 4.763 | 1.910E−06     | 1.438     | 2.390     |
| ANO1      | 0.520| 1.682      | 4.740 | 2.130E−06     | 1.357     | 2.086     |
| Ckap2L    | 0.525| 1.690      | 4.739 | 2.150E−06     | 1.360     | 2.100     |
| CEPP5     | 0.517| 1.677      | 4.690 | 2.730E−06     | 1.351     | 2.081     |
| ADGRG6    | 0.437| 1.548      | 4.686 | 2.780E−06     | 1.289     | 1.858     |
| CA12      | 0.278| 1.321      | 4.683 | 2.830E−06     | 1.176     | 1.484     |
| DLGAP5    | 0.507| 1.660      | 4.665 | 3.090E−06     | 1.342     | 2.054     |
| DEPCD1    | 0.423| 1.527      | 4.614 | 3.940E−06     | 1.276     | 1.828     |
| EREG      | 0.205| 1.227      | 4.610 | 4.030E−06     | 1.125     | 1.339     |
| MMP28     | 0.397| 1.488      | 4.601 | 4.210E−06     | 1.256     | 1.762     |
| TPX2      | 0.457| 1.580      | 4.587 | 4.500E−06     | 1.299     | 1.920     |
| CENPE     | 0.600| 1.822      | 4.585 | 4.540E−06     | 1.410     | 2.355     |
| INPP4B    | 0.543| 1.722      | 4.566 | 4.970E−06     | 1.363     | 2.174     |
| GPR87     | 0.188| 1.207      | 4.566 | 4.980E−06     | 1.113     | 1.309     |

(See figure on next page.)

**Fig. 4** A five‑gene prognostic signature for PC. A Patient characteristics are ranked according to the risk score. From the top to bottom, they are the risk score of the samples in the high and low risk groups, the distribution of survival status, and the heat map of the five genes. The dotted line indicates the patients in the high and low risk groups divided by the median risk score of 1.273. The left side of the dotted line is low risk, the right side is high risk, and the risk value of patients from left to right increases in turn. B Kaplan–Meier survival curve of samples from high and low risk groups. C Time‑dependent ROC curve for the survival of PC patients predicted by risk score. D Expression of the five genes in high‑and low‑risk groups.
Fig. 4 (See legend on previous page.)
serum (Corning, USA) and 1% penicillin/streptomycin (Gibco, USA) in a saturated humidity environment at 37 °C and 5% CO2. For CKI incubation [41], CKI (total alkaloid concentration of 25 mg mL\(^{-1}\)) was diluted with DMEM (CKI concentrations: 0.125, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0 mg mL\(^{-1}\), using the doubling dilution method, based on the total alkaloid concentration in CKI).

The proliferation of Panc-1 cells was detected by Cell Counting Kit-8 (CCK-8, Dojindo, Japan) assay and 5-ethynyl-2-deoxyuridine (EdU) proliferation assay. In brief, after routine digestion, cells were blown into a single-cell suspension (2.0 × 10⁵ cells mL\(^{-1}\)) and seeded into 96-well plates (100 μL·well\(^{-1}\)), and cultured for 24 h, routinely. The cells were then cultured with a drug-containing medium for 24, 48 and 72 h respectively. After drug treatment, the CCK-8 solution was added into 96-well plates (10 μL·well\(^{-1}\)) and incubated for 4 h at 37 °C. Optical density (OD) was detected at 450 nm using a microplate reader (Molecular Devices, USA). EdU proliferation assay was performed by BeyoClick™ EdU Cell Proliferation Kit with Alexa Fluor 488 (Beyotime, China) and strictly followed the manufacturer’s protocol.

**Reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis**

RNA Easy Fast Cell Kit (Tiangen, China) was applied for total RNA isolation according to the manufacturer’s instruction. The quality of total RNA was accredited by SpectraMax Quick Drop readers (Molecular Devices, USA). Of the total RNA, 1 μg was used for cDNA synthesis following the ReverTra Ace qPCR RT Kit (Toyobo, Japan) instruction. RT-qPCR was performed to measure the relative expression of mRNA, using SYBR Green Realtime PCR Master Mix (Toyobo, Japan). GAPDH was used as a control and the 2^\(-\Delta\Delta Ct\) method was conducted for the data analysis. The primer sequence of target genes was synthesized by Sangon Biotech Co., Ltd (Shanghai, China, Table 1).

**Enzyme-linked immunosorbent assay (ELISA)**

Human AKT1 ELISA Kit, Human CDK1 ELISA Kit, Human JAK1 ELISA Kit, Human EGFR ELISA Kit, Human MAPK1 ELISA Kit and Human MAPK3 ELISA Kit (Sinobestbio, China) were used to detect the protein expression of 6 core targets following the manufacturer’s instructions.

**Western blot assay**

Panc-1 cells were collected in RIPA lysis buffer and centrifuged at 13,000 rpm and 4 °C for 10 min. The supernatants were preserved and used for western blot assay. Total protein concentration was gauged by BCA Protein Assay Kit (Solarbio, China). 20 μg of total protein was mixed with 5 × sample buffer, boiled at 99 °C for 5 min and loaded onto 10% SDS-PAGE gels. Then the protein bands were transferred onto NC membranes and blocked with 5% non-fat milk or 5% bovine serum albumin (BSA) for 2 h at room temperature. The NC membranes with proteins were incubated with diluted primary antibodies (Affinity or Proteintech, China) at 4 °C overnight, including anti-AKT1 (1:500), anti-phospho-AKT1 (p-AKT1, 1:500), anti-CDK1 (1:500), anti-phospho-CDK1 (p-CDK1, 1:1000), anti-JAK1 (1:500), anti-phospho-JAK1 (p-JAK1, 1:500), anti-EGFR (1:500), anti-phospho-EGFR (p-EGFR, 1:500), anti-MAPK3/MAPK1 (1:500), anti-phospho-MAPK3/MAPK1 (p-MAPK3/1, 1:500) and anti-β-Tubulin (1:2000) antibodies. Then, membranes were incubated with relative sources of secondary antibodies (1:5000) at room temperature for 1.5 h. At last, the specific protein bands were recognized with immobilon western chemiluminescent HRP substrate (Millipore-Sigma, USA). Image J software was used for image analysis and the signals of specific proteins were normalized to β-Tubulin.

**Statistical analysis**

Data were presented as mean ± SD and statistical analysis was performed with the two-tailed unpaired Student’s t-test using GraphPad Prism 9.0 software. In all statistical analyses, statistical significance was indicated by a single asterisk (*: P < 0.05), two asterisks (**: P < 0.01).

**Results**

**WGCNA module construction**

In this study, a total of 177 samples and 5000 genes were screened for WGCNA analysis. All samples were retained as no outliers were found in the cluster analysis of the samples. In this study, a power value of β = 9 (R² = 0.85) was selected according to the scale-free criterion to construct the gene co-expression network (Fig. 2A). Then, a hierarchical clustering tree was built, and gene modules were identified using the dynamic tree cut method. The minimum number of genes in each module was set to 30. Similar expression modules were merged and 11 modules
Fig. 5 (See legend on previous page.)
were obtained (Fig. 2B). In addition, the TOM was visualized with a heatmap that could depict adjacencies or topological overlaps (Fig. 2C).

**Correlation analysis between modules and clinical traits**
The results and discussion may be presented separately or in a combined section and can optionally be divided into headed subsections. In this study, we calculated the correlation between gene modules and clinical traits such as race, age, new tumour event, vital status, grade, and stage of patients with PC. The Pearson correlation coefficient of ME and the corresponding variables was employed to represent the correlation between modules and the corresponding clinical information. As shown in Fig. 2D, the correlation between the black module and grade was greater than other modules, and the correlation between the blue module and stage was greater than other modules. Therefore, these two modules were selected for further investigation.

**Hub genes screening**
When screening the network of black and blue gene modules with the weight of Cutoff = 0.1 as the threshold, the black module consisted of 6173 gene linkages and 132 genes, and the blue module consisted of 4145 gene linkages and genes. Cytoscape was used to visualize the top 100 genes in the black and blue modules respectively (Fig. 3A, B). In addition, CytoHubba was used to analyze the network to determine the top 5 genes of the MCC score as hub genes (Fig. 3C, D). The hub genes of the black module are: non-SMC condensin 1 complex subunit G (NCAPG), mitotic checkpoint serine/threonine-protein kinase BUB1 (BUB1), cyclin-dependent kinase 1 (CDK1), targeting protein for Xklp2 (TPX2) and disks large-associated protein 5 (DLGAP5). The hub genes of the blue module are: innate immunity activator protein (INAVA), macrophage-stimulating protein receptor (MST1R), transmembrane protease serine 4 (TMPRSS4), transmembrane protein 92 (TMEM92) and 14-3-3 protein sigma (SFN).

**Survival analysis**
The univariate Cox proportional hazards regression analysis was used to study the correlation between mRNAs selected in the black and blue modules and survival time. Twenty-four genes related to survival time were selected based on \( P < 5 \times 10^{-6} \). The results of the univariate Cox proportional hazards regression are shown in Table 2. In addition, the results of multivariate Cox proportional hazards regression analysis showed that one gene (TSPOAP1) with HR < 1 was identified as a protective prognostic gene (positively correlated with the survival time of the patient); four genes (ADGRG6, GPR87, FAM111B, MMP28) with HR > 1 were identified as risky prognostic genes (inversely associated with the survival time of patients, Fig. 3E). The regression coefficients of the multivariate Cox proportional hazards regression analysis of the 5 genes were extracted to construct a prognostic risk scoring model:

\[
\text{Risk score} = (-0.292 \times \text{TSPOAP1 expression}) + (0.242 \times \text{ADGRG6 expression}) + (0.107 \times \text{GPR87 expression}) + (0.376 \times \text{FAM111B expression}) + (0.169 \times \text{MMP28 expression})
\]
| No. | Theoretical value | PPM | Time (min) | MS/MS ions                                                                 | Structure       | Resumption          |
|-----|-------------------|-----|------------|----------------------------------------------------------------------------|-----------------|---------------------|
| 1   | 218.10577         | −4.06 | 6.007     | 152.01067, 123.00785, 108.02056, 85.02821, 151.03957                      | ![Structure](#) | N-methylcytisine   |
| 2   | 246.17360         | 2.94  | 2.135     | 163.07516, 134.09622, 59.04988                                           | ![Structure](#) | Sophocarpine       |
| 3   | 248.18896         | −3.67 | 2.351     | 179.05530, 161.04527, 89.02322                                           | ![Structure](#) | Sophoridine        |
| 4   | 248.18910         | −3.17 | 1.834     | 176.3145, 148.2457, 112.2569                                             | ![Structure](#) | Matrine            |
| 5   | 262.16841         | −3.65 | 2.592     | 181.05049, 119.03400, 89.02325                                           | ![Structure](#) | Oxysophocarpine    |
| 6   | 264.18394         | −0.52 | 24.975    | 247.2548, 205.7581, 148.2567                                             | ![Structure](#) | Oxymatrine         |
| 7   | 264.18395         | −3.19 | 50.755    | 211.06097, 167.07062, 149.05995, 123.04412, 71.01385                    | ![Structure](#) | Sophoranol         |
| 8   | 384.22630         | 4.13  | 3.381     | 110.0603, 96.04457, 94.06555, 92.04989, 67.05498                         | ![Structure](#) | Macrozamin         |
| 9   | 446.12215         | −2.50 | 2.976     | 263.07761, 221.06653, 179.05548, 161.04482                               | ![Structure](#) | Trifolirhizin      |
| 10  | 764.25163         | 0.84  | 17.229    | 152.01073, 123.04407, 108.0206,                                          | ![Structure](#) | Liriodendrin       |
Eighty-eight patients with a risk score higher than the median risk score (1.273) were assigned to the high-risk group, while the remaining 89 patients were assigned to the low-risk group (Fig. 4A). The Kaplan–Meier survival analysis showed a highly significant difference in OS was detected between the high- and low-risk groups (Log-rank test \( P < 0.0001 \)), suggesting that the expression of these 5 genes can be effectively distinguished the high- and low-risk of these PC patients (Fig. 4B and Fig. 5). Similarly, the hub targets of PC had a very strong correlation with the survival time of PC patients (Additional file 1: Fig. S1). The area under the time-dependent...
Fig. 8 (See legend on previous page.)
The ROC curve of the 1-year, 3-year and 5-year survival rates of the patients were 0.751, 0.811 and 0.872, respectively, indicating that the prognostic gene model had good prediction accuracy (Fig. 4C). Figure 4D shows the distribution of the expression levels of the five genes in high- and low-risk groups. Then, we used the GSE15471 (GPL570) dataset from the GEO database as the external validation dataset of WGCNA results. Its pairs of normal and tumor tissue samples were obtained at the time of surgery from resected pancreas of 36 pancreatic cancer patients. Consistent with the WGCNA results, in the GSE15471 dataset, the TSPOAP1 in the tumor group was significantly lower expressed, while the ADGRG6, GPR87, FAM111B and MMP28 were significantly higher expressed compared with the normal group (Additional file 2: Fig. S2).

Compound-putative target network

In our study, 10 marker ingredients of CKI were identified by HPLC–MS (Fig. 6; Table 3). Concurrently, we also supplemented the chemical ingredients by literature research [10, 42]. Collectively, a total of 16 active ingredients in CKI were selected for the next in-depth study, which included 9α-hydroxymatrine, adenine, baptifoline, isomatrine, lamprolobine, piscidic acid and the 10 compounds detected by HPLC–MS. The 16 chemical components of CKI are shown in the Additional file 3: Table S1. The compound-putative target network includes 301 nodes (16 compound nodes and 285 target nodes) and 636 edges (Fig. 7A).

Table 4 Docking results of 6 core targets and related compounds

| Targets | PDB ID | Compound       | Affinity (kcal mol⁻¹) |
|---------|--------|----------------|----------------------|
| AKT1    | 6CCY   | Adenine        | −5.0                 |
| MAPK1   | 5NHH   | Adenine        | −4.9                 |
| MAPK3   | 4QTB   | Adenine        | −5.4                 |
| EGFR    | 1XXK   | Adenine, N-methylcytisine | −5.4  |
| CDK1    | 5LQF   | Adenine        | −5.1                 |
| CDK1    | 5LQF   | Lamprolobine   | −8.6                 |
| JAK1    | 3EYH   | 9α-Hydroxymatrine | −7.8          |
| JAK1    | 3EYH   | Sophoranol     | −7.6                 |

Genes associated with PC

After analysis of the RNA sequencing data, 623 DEGs were identified. In addition, 71 PC-related genes were obtained from the TTD database. Furthermore, 10 hub genes and 5 prognosis-related genes were integrated with the above genes. After deleting duplicate genes, a total of 702 genes were obtained (Additional file 4: Table S2).

CKI-PC PPI network and core targets identification

PPI networks have been proven to be conducive to explaining complex interactions between multiple proteins in some complex diseases (including cancer) [43]. In order to gain an in-depth understanding of the complex interactions between the intersection targets and further explore the potential mechanism of CKI in the treatment of PC, we construct a CKI-PC PPI network. As shown in Fig. 7A, the network consists of 64 nodes (24 intersection targets of compound targets and PC targets, and 40 other human proteins) and 480 edges. The network analysis showed that the average values of "degree", "betweenness" and "closeness" of the nodes were 15, 0.018331626 and 0.497056362, respectively. In this study, the nodes whose "degree", "betweenness" and "closeness" were all greater than the corresponding average value were selected as key nodes of the network. Finally, a total of 15 potential key targets were obtained, namely AKT1, MAPK1, CCNB1, MAPK3, EGFR, STAT3, PPP2CA, CDC25C, EGF, PTPN1, CCNA2, AURKA, BIRC5, CDK1 and JAK1 (Additional file 5: Table S3). The network module is defined as a set of highly interconnected nodes that help to discover and reveal hidden biological information in the network [44]. In this study, a CKI-PC PPI network was divided into 4 modules, and finally, the first 3 modules with scores greater than 4.5 were selected as the key modules (Fig. 7B–E). Among all the 15 potential key targets, 6 targets were clustered in these 3 modules and were directly related to the compound, which were confirmed to be the core targets. The six core targets are RAC-alpha serine/threonine-protein kinase (AKT1), mitogen-activated protein kinase 1 (MAPK1), Mitogen-activated protein kinase 3 (MAPK3), epidermal growth factor receptor (EGFR), cyclin-dependent kinases 1 (CDK1) and protein tyrosine kinase (janus kinase 1, JAK1).

![Fig. 9 Multipathway mechanism of CKI treating PC. A Important pathways in the 3 key modules. The red letters represent the core genes enriched in these pathways. B Drug-Compound-PPI Target-Pathway network. Blue octagon represents CKI, green triangles represent compound related to intersection targets, yellow rectangles represent intersection targets of compound targets and PC targets, the red rectangles represent other human proteins, and the purple diamonds represent the relevant pathways enriched by the three modules.](image-url)
Fig. 9 (See legend on previous page.)
**GO and KEGG enrichment analysis**

In the current study, the biological processes (BP), molecular functions (MF), cellular components (CC) and signalling pathways involved in the three key modules were further explored through GO enrichment and KEGG pathway enrichment analysis. The GO enrichment analysis showed that module 1 was closely related to the cell cycle and cell proliferation; module 2 was closely related to JAK-STAT, MAPK cascade, phosphatidylinositol-mediated signalling, phosphorylation, and negative regulation of the apoptotic process; and module 3 was closely related to protein tyrosine kinase activity and MAPK cascade (Fig. 8A). The KEGG pathway enrichment analysis showed that module 1 was mainly associated with the cell cycle; module 2 was mainly associated with cancer pathway, ErbB signalling pathway, PI3K-Akt signalling pathway, mTOR signalling pathway; and module 3 was associated with PI3K-Akt signalling pathway (Fig. 8B). Figure 9A shows the important pathways in the three modules. To wholly and systematically explain the mechanism of CKI treating PC, Cytoscape software was utilized to construct a Drug-Compound-PPI Target-Pathway network. As shown in Fig. 9B, the network consists of 102 nodes (1 node of CKI, 12 nodes of compounds related to intersection targets, 64 nodes of PPI targets, 25 nodes of pathways enriched by three modules) and 723 edges.

**Molecular docking**

To explore the binding methods between core targets and related CKI compounds, the 6 targets, including AKT1, MAPK1, MAPK3, EGFR, CDK1 and JAK1 were used for molecular docking verification. The crystal structures of the 6 targets were retrieved from the PDB database and the 3D structures of the 5 compounds (adenine, N-methylcytisine, lamprolobine, 9α-hydroxymatrine and sophoranol) were downloaded from the PubChem database. The docking operation (the docking results are shown in Table 4) was performed by AutoDock Vina. Figure 10 shows the binding methods between compounds and targets. Adenine mainly forms 2 hydrogen bonds with residues Ala230 and Glu228 on AKT1 protein, and a total of 4 residues bind to the protein by hydrophobic interaction. Lamprolobine mainly forms a hydrogen bond with the Arg1007 residue on the JAK1 protein, and a total of 2 residues bind to the protein by hydrophobic interaction. Sophoranol mainly forms a hydrogen bond with the Arg1007 residue on the JAK1 protein, and a total of 4 residues bind to the protein by hydrophobic interaction. Sophoranol mainly forms a hydrogen bond with the Gly13 residue on the CDK1 protein, and a total of 8 residues are bound to the protein by hydrophobic interaction. 9α-hydroxymatrine mainly forms 2 hydrogen bonds with Gly1020 and Asp1021 residues on JAK1 protein, and a total of 4 residues bind to the protein by hydrophobic interaction. N-methylcytisine mainly forms a hydrogen bond with the Gly13 residue on the CDK1 protein, and a total of 2 residues bind to the protein by hydrophobic interaction.

**Anti-PC effect of CKI and core targets verification**

Panc-1 cells were used to observe the anti-proliferation effect of CKI in PC treatment. Figure 11A exhibited that CKI had similar inhibitory proliferation effects at 24 h, 48 h and 72 h incubation time. Specifically, it was found that the half-maximal inhibitory concentration (IC₅₀) values of CKI on panc-1 cells at 24 h was found to be 3.38 ± 1.40 mg mL⁻¹. And after 48 h and 72 h, the IC₅₀ values of CKI were 2.20 ± 0.54 mg mL⁻¹ and 1.84 ± 0.38 mg mL⁻¹ respectively. Based on the IC₅₀ values and cellular state, 48 h incubated time was chosen for the EdU incorporation assay. The EdU incorporation assay showed that (Fig. 11B, C), EdU positive cells were significantly reduced (P<0.05 or P<0.01) in all CKI groups compared with the control group. It confirmed that CKI could restrain the strong proliferation of PC cells.

In addition, we also used RT-qPCR assay to analyse the regulatory effects of CKI on core genes (AKT1, CDK1, JAK1, EGFR, MAPK1 and MAPK3) to evaluate the mechanism of CKI in PC treatment. As shown in Fig. 11D, CKI
Fig. 10 (See legend on previous page.)
significantly inhibited the expression of CDK1, JAK1, EGFR, MAPK1 and MAPK3 (all \( P < 0.05 \)). However, AKT1 results showed no significant difference in all CKI groups compared with the control group (\( P > 0.05 \)). We followed up with validation experiments on the protein expression levels of the core targets. ELISA results showed that there was no significant difference in total protein content of AKT1, CDK1, JAK1, EGFR, MAPK1 and MAPK3 in the cytoplasm after CKI intervention (all \( P > 0.05 \), Fig. 12A). Considering that the phosphorylation levels of these proteins were the markers of their own activation or mediated activation of related pathways, we examined the expression levels of their phosphorylated proteins by western blot. Interestingly, after CKI intervention, the expression levels of phosphorylated CDK1, JAK1, EGFR, MAPK1 and MAPK3 were significantly reduced compared with the control cells (all \( P < 0.05 \), Fig. 12B, C). This was consistent with the results of mRNA expression.

**Discussion**

Currently, pancreatic cancer, with high metastasis and a 5-year survival rate of less than 8% of malignant tumours, is responsible for about the same number of deaths due to its poor prognosis [1, 4]. Understanding the pathogenic mechanisms of PC, especially the key survival-related targets associated with clinical information, can be useful in identifying biomarkers for early diagnosis and prognosis [45]. It is reported that FAM111B mutation may be associated with PC predisposition based on clinical and molecular evidence [46]. Cancer stem cells are of crucial importance in drug resistance and tumour relapse. Moreover, patients with high GPR87 showed a poorer prognosis. Further studies assumed that GPR87 promotes the proliferation of PC stem cells, thus enhancing the malignancy of tumour [47]. Recently, ncRNAs have played a distinctive role in cancer development and immune regulation [48]. As regulatory targets of some ncRNAs, TSPOAPI, ADGRG6, MMP28 and other genes are particularly important in the initiation, progression of various cancers such as PC. Moreover, their mutations are closely related to immune infiltration and survival rate [49–51]. Therefore, we can speculate that these 5 genes, which may play important roles in PC carcinogenesis, progression and prognosis, could become the PC candidate biomarkers.

Although network pharmacology features high-throughput, systematic and holistic research, it also has many limitations, such as the lack of clinical information [52]. Here, WGCNA analysis is a novel systems biology approach to classify highly co-expressed genes and connect them in the network [17]. And the sub-network regions, are called modules, can be associated with clinical parameters such as cancer status or patient survival [53]. Within our study, the WGCNA results showed that the black and blue modules had the highest correlation with tumour grade and tumour stage, respectively, and both were also strongly associated with patient survival status. Further multivariate Cox proportional hazards regression analysis revealed that among the 5 survival time-related genes, TSPOAPI was the protective gene; in contrast, ADGRG6, GPR87, FAM111B and MMP28 were the risk genes. Remarkably, GPR87-mediated activation of the JAK/STAT signalling pathway promoted the expansion of PC stem cells, contributing to the chemotherapy resistance of PC cells [47]. To extend, GPR87 trans-activated EGFR to promote scattering and extension of tumour cells [17]. Based on the analysis of tumour and para-tumour tissues of clinical samples with RNA sequencing, it was found that GPR87 and MAPKs were significantly differentially expressed genes [54]. Similarly, a comprehensive whole-genome, transcriptome and clinical dataset called the POG570 cohort, had revealed that alterations in EGFR, ADGRG6, and other genes were involved in tumour drug resistance and sensitivity, as well as recurrent noncoding events [50]. ADGRG6 can also form carcinogenic fusion variants with ROS1 to promote the development of EGFR-tyrosine kinase inhibitor resistance in cancer patients with EGFR mutation [55]. ADGRG6 also promoted tumour-stromal angiogenesis and hypoxia-induced retinal angiogenesis through the GATA2/STAT5/VEGF/MAPKs signalling pathway. More than that, activated VEGF can further activate STAT5 through phosphorylated JAK2, enhancing the STAT5/VEGF/MAPKs signalling pathway response [56]. Conversely, knockdown of ADGRG6 results in low expression of HDAC2 and GLI2, and inhibits proliferation and arrests cell cycle in cancer cells [57]. On the likeness, FAM111B, as a degradative enzyme, degrades p16 and other genes, that could regulate cyclin D1-CDK4-dependent cell cycle progression leading to poor outcomes [58]. Moreover, the high expression of CDK1 and MMP28 are jointly
Fig. 11 (See legend on previous page.)
regulated by the upstream RACGAP1, which is involved in the pathogenesis, cell cycle progression, migration and invasion of PC cells [49]. MAPK signalling pathway activated by nicotinic cholinergic receptors (NCRs) can enhance tumour cell proliferation, accompanied by increased expression of MMP2 and MMP28 genes [59]. Therefore, these genes (CDKs, JAKs, STATs, MAPKs and EGFR) deserve further exploration in PC pathogenesis in addition to the 5 survival-dependent genes described.

Interestingly, in this study, the 5 core genes CDK1, JAK1, EGFR, MAPK1, and MAPK3 targeted by CKI were investigated by WGCNA and network pharmacology analysis and then verified by in vitro experiments. MAPKs, a class of serine/threonine protein kinases that has four different types (ERKs, P38, JNK, and ERK5) in mammals [60]. MAPK1 is significantly upregulated in multiple types of cancer. Overexpression of MAPK1 induces EMT and is associated with tumour cell proliferation, apoptosis, invasion, and metastasis [61–63]. MAPK1 has been proved to be strongly associated with invasion of pancreatic ductal adenocarcinoma cells [64]. In addition, a bioinformatics study showed that MAPK1 is overexpressed in PC and is associated with poor prognosis in PC patients [65]. Aberrant expression of MAPK3 is related to invasion, metastasis and drug resistance of various tumour cells [66]. Bioinformatics studies revealed that MAPK3 is a core gene associated with PC [67]. In addition, it has been reported that activated MAPK3/1 (ERK1/2) overexpression in PC, and the activity of ERK1/2 can protect PC cells from chemotherapy-induced apoptosis [68]. Other studies have shown that phosphorylation of ERK1/2 promotes proliferation, migration and invasion of pancreatic ductal adenocarcinoma cells [69]. Fortunately, matrine and oxymatrine, both of which are the main ingredients of CKI, have been shown to inhibit the phosphorylation of ERK1/2 [70, 71]. EGFR (ErbB1) belongs to the epidermal growth factor receptor (ErbB) family and is widely distributed on the cell surface of mammalian epithelial cells, glial cells and fibroblasts [72]. ErbB2, ErbB3 and ErbB4 also belong to the ErbB family. When combined with the ligands AR, TGF, and EGF, the combined products activate downstream genes such as MAPKs to regulate cell survival, proliferation, differentiation and migration [73].

EGFR is highly expressed in a variety of tumours, and is associated with tumour occurrence and development and poor prognosis [74, 75]. It has been reported that EGFR overexpression can be detected in up to 90% of PC tumour tissues, and that overexpressed EGFR is closely involved in the progression of PC and the poor prognosis of PC patients [76, 77]. It was also confirmed that EGFR is an effective target for PC prevention and treatment [78]. In addition, oxymatrine was found to effectively inhibit EGFR phosphorylation and EGFR-related signalling pathways, thereby inhibiting gastric cell proliferation and invasion [79]. Not only that, matrine and oxymatrine are EGFR-targeted components and can act on EGFR similarly as a control drug gefitinib [80]. CDK1 is closely related to the cell cycle [81]. At the same time, overexpressed CDK1 is associated with PC development and poor prognosis of patients [82]. Besides, CKI has been proven to have an inhibitory effect on CDK1 [83]. Matrine arrests the cell cycle and induces apoptosis in several cancer cell lines, and the mechanism is downregulated cell cycle-related proteins CDK1, Cyclin B1 and Cyclin D1 [84]. Oxymatrine has a similar mechanism as described above to arrest the cell cycle in glioblastoma cells. In detail, it inhibits phosphorylation of EGFR and STAT3, thereby inhibiting the expression of downstream cell cycle-related proteins (CDK1, CDK4 and CDK6) [85]. Coincidentally, it has been reported that Oxymatrine can simultaneously inhibit both EGFR/MAPK3/1 and EGFR/CDK1 pathways to arrest the cycle in multiple cancer cell lines [86]. Matrine, Oxymatrine, and Sophoridine can exert biological effects on multiple proteins in the cell cycle pathway of colorectal cancer cells, thereby arresting cell cycle pathway activation in a full range [87]. JAK is a non-transmembrane tyrosine kinase that can activate the STAT protein under the action of growth factors and cytokines [88]. JAK/STAT signalling pathway is continuously activated in tumour cells, and its inhibition would induce apoptosis of PC cells and their proliferation inhibition [89]. JAK1 is a member of the JAK protein family, which is closely related to the progression of various cancers [90]. Ruxolitinib, a JAK1/JAK2 inhibitor, can inhibit endothelial cell-mediated proliferation of PC cells [91]. It can also treat patients with pancreatic ductal adenocarcinoma who have the characteristics of angiogenesis.
Fig. 12 (See legend on previous page.)
genes by targeting JAK1 and TGF-β [92]. Matrine can also inhibit cell growth by inhibiting activation of the JAK1/STAT3 signalling pathway [93]. Oxymatrine plays a significant role in regulating cell proliferation and survival in tumor cells by inhibiting the activation of JAK1 and JAK2, thereby inhibiting the phosphorylation and nuclear translocation of STAT5 [94]. Consistent with these reports, our results illustrated that CKI can inhibit the proliferation of pancreatic cancer cells, arrest cell cycle and downregulate the expression levels of p-CDK1, p-JAK1, p-EGFR and pMAPK3/1.

Taken together, we can speculate that the molecular mechanisms of CKI in PC treatment are as follows: (1) CKI inhibits proliferation of PC cells via inhibition of the EGFR transactivation, and downregulation of the NCR-mediated MAPK pathway; (2) CKI inhibits expansion of PC stem cells via inactivation of the GPR87/JAK/STAT pathway; (3) CKI arrests cell cycle progression of PC cells via inhibition of the FAM111B/p16/CDK pathway; (4) CKI inhibits migration and invasion of PC cells via downregulation of the NCR-mediated MAPK/MMP pathway; (5) CKI reverses chemo-resistance of PC cells via inhibition of the ROS1-ADGRG6/EGFR pathway; (6) CKI inhibits tumour angiogenesis of PC via inhibition of the ADGRG6/GATA2/STAT5/VEGF/MAPK pathway. However, these speculations should be supported by further basic and clinical experimental data.

Conclusions
In summary, this study demonstrated a strategy to optimize conventional network pharmacology, and then explained that the molecular mechanism of CKI treating PC was closely associated with 5 core genes (including CDK1, JAK1, EGFR, MAPK1 and MAPK3), which were related to important signalling pathways (including cell cycle, JAK/STAT and ErbB pathway) and survival-correlated genes (including TSPOAP1, ADGRG6, GPR87, FAM111B and MMP28). These findings may be useful for clinical decision-making and guidance for rational clinical use of CKI in PC treatment.

Abbreviations
CKI: Compound kushen injection; PC: Pancreatic cancer; WGCNA: Weighted gene co-expression network analysis; TCM: Traditional Chinese medicine; TCGA: The cancer genome atlas; TOM: Topological overlap measure; ME: Module eigengene; MM: Module membership; GS: Gene significance; MCC: Maximal clique centrality; HR: Hazard ratio; CI: Confidence interval; ROC: Receiver operating characteristic; AUC: Area under curve; TCMSP: Traditional Chinese medicine systems pharmacology database and analysis platform; STITCH: Search tool for interactions of chemicals; STRING: Search tool for the retrieval of interacting genes/proteins; PPI: Protein–protein interaction; MCODE: Molecular complex detection; GO: Gene ontology; KEGG: Kyoto encyclopedia of genes and genomes; SD: Standard deviation; PDB: Protein data bank; TTD: Therapeutic target database; CDK1: Cyclin-dependent kinase 1; MAPK1: Mitogen-activated protein kinase 1; MAPK3: Mitogen-activated protein kinase 3; EGF: Epidermal growth factor receptor; JAK1: Janus kinase 1.
References

1. Rawla P, Sunkara T, Gaddipati V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10:10–27.

2. Dong Z, Xu WH, Lu P, Wu N, Liu J, Ruan B, et al. MicroRNA-135a inhibits cell proliferation by targeting Bmi1 in pancreatic ductal adenocarcinoma. Int J Biol Sci. 2014;10:733–45.

3. Vincent A, Herman J, Schlicker R, Huban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607–20.

4. Sun H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

5. Bao C, Lu Y, Chen J, Chen D, Lou W, Ding B, et al. Exploring specific prognostic biomarkers in triple-negative breast cancer. Cell Death Dis. 2019;10:807.

6. Long J, Huang S, Bai Y, Mao J, Wang A, Lin Y, et al. Transcriptional landscape of cholangiocarcinoma revealed by weighted gene coexpression network analysis. Brief Bioinform. 2021;22:bbaa224.

7. Wang L, Li L, Wang X, Guo G, Liu R, Zhang S, et al. Clinical study on compound Sophora flavescens radix (kushen) injection combined with gamma knife for treatment of locally advanced pancreatic carcinoma. Chin J Integr Med. 2015;22:21–4 (Chinese).

8. Wang W, You RL, Qin WJ, Hai LN, Fang MJ, Huang GH, et al. The therapeutic efficacy of Jiawei Foshou san combined with chemotherapy on human pancreatic cancer. Zhong Guo Yi Xue Za Zhi. 2015;42:1736–40 (Chinese).

9. Wang L, Li L, Wang X, Guo G, Liu R, Zhang S, et al. Clinical study on compound Sophora flavescens radix (kushen) injection combined with gamma knife for treatment of locally advanced pancreatic carcinoma. Chin J Integr Med. 2015;22:21–4 (Chinese).

10. Wang W, You RL, Qin WJ, Hai LN, Fang MJ, Huang GH, et al. Understanding the mechanistic contribution of herbal extracts in compound kushen injection with transcriptome analysis. Front Oncol. 2019;9:6332.

11. Wang W, You RL, Qin WJ, Hai LN, Fang MJ, Huang GH, et al. Anti-tumor activities of active ingredients in compound kushen injection. Acta Pharmacol Sin. 2015;36:676–79.

12. Yang Y, Sun M, Yao W, Wang F, Li X, Wang W, et al. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib. J Immunother Cancer. 2020;8:e000317.
45. Walsh N, Zhang H, Hyland PL, Yang Q, Mocci E, Zhang M, et al. Agnostic pathway/gene set analysis of genome-wide association data identifies associations for pancreatic cancer. Jnci-J Natl Cancer. 2019(11):557–67.
46. Mercier S, Kury S, Nahon S, Salort-Campana E, Barbarot S, Bézieau S. FAM111B mutation is associated with pancreatic cancer predisposition. Pancreas. 2019;48:841–2.
47. Jiang J, Yu C, Guo X, Zhang H, Tian S, Cai K, et al. G protein-coupled receptor GPR87 promotes the expansion of PDA stem cells through activating JAK2/STAT3. Mol Ther Nucleic Acids. 2020;21:384–93.
48. Liu Z, Pan H, Xin L, Zhang Y, Zhang W, Cao P, et al. Circ-ZNF609 promotes carcinogenesis of gastric cancer cells by inhibiting miRNA-145-3p expression. Eur Rev Med Pharmacol Sci. 2019;23:9441.
49. Khalid M, Idichi T, Seki N, Wada M, Yamada Y, Fukushima H, et al. Gene regulation by antitumor miR-204-5p in pancreatic ductal adenocarcinoma: the clinical significance of direct RACGAP1 regulation. Cancers. 2019;11:327.
50. Pleasance E, Timmuss E, Williamson L, Kwan H, Culibrk L, Zhao EY, et al. Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. Nat Cancer. 2020;2:452–68.
51. Tang X, Zhang M, Sun L, Xu F, Peng X, Zhang Y, et al. The biological function delineated across pan-cancer levels through IncRNA-based prognostic risk assessment factors for pancreatic cancer. Front Cell Dev Biol. 2021;9:694652.
52. Song Y, Wang C, Pan Y, Liu T. Investigating the multi-target pharmacological mechanism of Hedychium diffusum wild acting on prostate cancer: a network pharmacology approach. Biomolecules. 2019;9:591.
53. Wu C, Zhou F, Ren J, Li X, Jiang Y, Ma S. A selective review of multi-level omics data integration using variable selection. High Throughput. 2019;8:4.
54. Wang J, Xu C, Cheng Q, Zhao J, Wu S, Li W, et al. RNA sequencing revealed signals of evolution from gallbladder stone to gallbladder carcinoma. Front Oncol. 2020;10:823.
55. Xu S, Wang W, Xu C, Li X, Ye J, Zhu Y, et al. ROS1-ADGRG6: a case report of a novel ROS1 oncopgenic fusion variant in lung adenocarcinoma and the response to crenotinib. BMC Cancer. 2019;19:769.
56. Cui H, Wang Y, Huang H, Yu W, Bao M, Zhang L, et al. GPR126 protein regulates developmental and pathological angiogenesis through modulation of VEGFR2 receptor signaling. J Biol Chem. 2014;289:34871–85.
57. Cui H, Yu W, Wu M, Luo Y, Yang M, Cong R, et al. GPR126 regulates colorectal cancer cell proliferation by mediating HDAC2 and GLI2 expression. Proc Natl Acad Sci U S A. 2019;116:23453–6.
58. Wang J, Xu C, Cheng Q, Zhao J, Wu S, Li W, et al. RNA sequencing revealed signals of evolution from gallbladder stone to gallbladder carcinoma. Front Oncol. 2020;10:823.
59. Manuela R, Mario M, Vincenzo R, Filippo R. Nicotine stimulation increases proliferation of KRAS-driven lung adenocarcinoma cell lines. Front Genet. 2019;10:5246–52.
60. Wu CX, Wang XQ, Chok SH, Man K, Tsang S, Chan A, et al. Blocking CDK1/PDK1/beta-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma: Theranostics. 2018;8:3737–50.
61. Dong S, Huang F, Zhang H, Chen Q. Overexpression of BUB1B, CNOT2, CDC20, and CDK1 in tumor tissues predicts poor survival in pancreatic ductal adenocarcinoma. Biosci Rep. 2019;39:BSR20182306.
62. Cui J, Qui Z, Harata-Lee Y, Nwe AT, Shen H, Wang W, et al. Cell cycle, energy metabolism and DNA repair pathways in cancer cells are suppressed by compound kushen injection. BMC Cancer. 2019;19:103.
63. Chang J, Hu S, Wang W, Li Y, Zhi W, Su S, et al. Matrine inhibits prostate cancer via activation of the unfolded protein response/endoplasmic reticulum stress signaling and reversal of epithelial to mesenchymal transition. Mol Med Rep. 2018;18(1):945–57.
64. Dai Z, Wang L, Wang X, Zhao B, Zhao W, Bhardwaj S, et al. Oxytetracycline induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the ERG/FRK/P53/Akt/mTOR signaling pathway and STAT3. Oncol Rep. 2018;40(2):867–76.
65. Halim CE, Xinjing SL, Fan L, Bailey Vitarbo J, Arfuso F, Tan CH, et al. Anti-cancer effects of oxytetracycline are mediated through multiple molecular mechanisms(s) in tumor models. Pharmacol Res. 2019;147:104327.
66. Chen M, Gu Y, Zhang AL, Sze DM, Mo S, May BH. Biological effects and mechanisms of matrine and other constituents of Sophora flavescens in colorectal cancer. Pharmacol Res. 2021;171:105777.
67. Sabino J, Verstoeck B, Vermeire S, Ferrante M. New biologics and small molecules in inflammatory bowel disease: an update. Therap Adv Gastroenterol. 2019;12:321925224.
89. Yang L, Wei WC, Meng XN, Gao J, Guo N, Wu FT, et al. Significance of IL28RA in diagnosis of early pancreatic cancer and its regulation to pancreatic cancer cells by JAK/STAT signaling pathway - effects of IL28RA on pancreatic cancer. Eur Rev Med Pharmacol Sci. 2019;23:9863–70.

90. Bi CL, Zhang YQ, Li B, Guo M, Fu YL. MicroRNA-520a-3p suppresses epithelial-mesenchymal transition, invasion, and migration of papillary thyroid carcinoma cells via the JAK1-mediated JAK/STAT signaling pathway. J Cell Physiol. 2019;234:4054–67.

91. Gore J, Craven KE, Wilson JL, Cote GA, Cheng M, Nguyen HV, et al. TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis. Oncotarget. 2015;6:7504–21.

92. Craven KE, Gore J, Wilson JL, Korc M. Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes. Oncotarget. 2016;7:323–41.

93. Chen SF, Zhang ZY, Zhang JL. Matrine increases the inhibitory effects of afatinib on H1975 cells via the IL6/JAK1/STAT3 signaling pathway. Mol Med Rep. 2017;16:2733–9.

94. Jung YY, Shanmugam MK, Narula AS, Kim C, Lee JH, Namjoshi OA, et al. Oxymatrine attenuates tumor growth and deactivates STAT5 signaling in a lung cancer xenograft model. Cancers. 2019;11:49.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.